MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Marketable securities -short term$228,638K Cash and cashequivalents$29,827K Prepaid and othercurrent assets$10,638K Investment tax creditsreceivable$822K Restricted investments$75K Total current assets$270,000K Marketable securities -long term$26,709K Operating lease right ofuse asset$7,105K Property and equipment,net$2,335K Other assets$1,375K Total assets$307,524K Total liabilities andshareholders' equity$307,524K Total shareholder'sequity$255,168K Liabilities, total$52,356K Accumulated deficit-$432,011K Accumulated othercomprehensive loss-$1,141K Common shares, no parvalue unlimited...$631,995K Note payable, net ofcurrent portion$24,910K Total currentliabilities$21,485K Operating leaseliabilities, net of current...$5,961K Additional paid-in capital$56,325K Accrued expenses andother current...$17,212K Operating leaseliabilities, current$2,287K Accounts payable$1,793K Current portion of notepayable$193K
Balance Sheet

enGene Therapeutics Inc. (ENGNW)

enGene Therapeutics Inc. (ENGNW)

source: myfinsight.com